Calluna's AURORA trial for CAL101 in IPF nears Q1 2027 lung-function data
The Phase 2 study finished enrollment early and moved its completion date up nine months, setting up a first efficacy test for an S100A4-targeted antibody in fibrotic lung disease.
Executive Summary
- Calluna Pharma AS has moved its Phase 2 IPF trial of CAL101 to full enrollment and pulled its completion timeline forward, positioning the study to deliver its first efficacy readout on schedule.
- The trial's single primary endpoint measures lung function decline against placebo, the standard bar in idiopathic pulmonary fibrosis drug development.
- CAL101 targets a DAMP protein with no other industry-sponsored trial pairing that target with this indication, placing the readout outside any established precedent for this specific mechanism-disease combination.
- The trial's early enrollment completion and accelerated completion date reflect execution ahead of guidance, not a sign of distress.
The trial
AURORA (NCT06736990) is a randomized, double-blind, placebo-controlled Phase 2 study evaluating CAL101, a monoclonal antibody targeting the DAMP protein S100A4, in adults with idiopathic pulmonary fibrosis. The trial enrolled patients with FVC at least 45% of predicted and DLCO at least 25% of predicted, randomizing them 3:2 to monthly intravenous infusions of CAL101 or placebo for six months following a 28-day screening period. Calluna said the study enrolled 161 adult patients across more than 50 sites in the US, UK, EU, Turkey and South Korea, finishing more than six months ahead of schedule. The trial's registry enrollment target lists 150 patients. NCT06736990+1A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisNCT06736990Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)Apr 22, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The endpoint
The primary endpoint is change from baseline in forced vital capacity (FVC) compared to placebo, the lung-function measure used across IPF drug development. Jonas Hallen, M.D., Ph.D., Co-Founder and Chief Medical Officer of Calluna Pharma, called the enrollment completion "an important operational milestone for Calluna," while Chief Executive Officer Mark Gaffney said AURORA "enables us to have a comprehensive understanding of CAL101 and its readiness for late-stage and pivotal studies in pulmonary fibrosis as well as its potential in other inflammatory or fibrotic diseases". A placebo-controlled Phase 1 study of CAL101 showed a favorable safety profile, predictable pharmacokinetics, and pharmacodynamic effects consistent with extracellular S100A4 neutralization. NCT06736990+1A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisNCT06736990Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)Apr 22, 2026
Timing shift
The trial's status moved from Recruiting to Active, not recruiting on April 27, 2026, the same day its primary completion date shifted from August 2027 to November 2026, a pull-forward of roughly nine months. Calluna guided to topline data in the first quarter of 2027, a window that opens after that primary completion date. The enrollment count held flat against its anticipated target of 150 patients, a change the underlying operational model flags as within the routine range rather than a deviation. NCT06736990+1A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisNCT06736990Calluna Pharma Completes Enrollment in Phase 2 AURORA Study of CAL101 for Idiopathic Pulmonary Fibrosis (IPF)Apr 22, 2026
Competitive frame
No other industry-sponsored trial pairs the S100A4 target with idiopathic pulmonary fibrosis, and the nearest mechanism neighbors are PI3K-delta inhibitors in blood cancers and lymphoma, a different disease setting on a different pathway. Idiopathic pulmonary fibrosis itself carries an active small-molecule pipeline, with more than 121 trials using that modality in the indication, including later-stage antifibrotic programs from Boehringer Ingelheim, Bristol-Myers Squibb and Sunshine Lake Pharma. Against that backdrop, S100A4 as a target for lung fibrosis has no resolved trial to benchmark against; a readout that shows an FVC benefit over placebo would be the result that distinguishes the mechanism in a field otherwise populated by antifibrotic small molecules with different modes of action.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.